The oral therapy is the first and only Janus kinase (JAK) inhibitor approved in the US for this patient population
News
Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.
Priority review for Astellas’ AML drug
Astellas Pharma’s gilteritinib is under priority review in the US as potential treatment for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.
Bayer/Loxo’s larotrectinib gets speedy review in the US
Bayer/Loxo Oncology’s larotrectinib has been granted a priority review by the US Food and Drug Administration, which will consider its use to treat metastatic solid tumours carrying a certain genetic mutation.
Trial to test cancer combo in both adults and children
UK researchers have launched an early stage trial designed to help assess whether AstraZeneca and MSD’s selumetinib could be effective in combination with dexamethasone as a treatment for leukaemia.
NHS England unveils £10m fund to retain GPs
NHS England has announced a new initiative to help retain GPs in the shape of a £10 million fund designed to capture those considering leaving general practice
US approves UCB’s Cimzia for psoriasis
Drug is the first Fc-free, PEGylated anti-TNF treatment option for this indication and marks UCB’s entry into immuno-dermatology
AB Sciences decides against re-examination of masitinib filing
Firm says re-examination procedure “would not be the most appropriate format” to address all concerns raised by the CHMP
Janssen terminates Darzalex/Tecentriq combo trial
Drug fails to show any benefit over Tecentriq alone in lung cancer.
Health and pharma link to tackle dementia in Greater Manchester
Partnership between Health Innovation Manchester, the Greater Manchester Health and Social Care Partnership, and the Dementia Industry Group will focus on finding the best care and treatment options
Try a different challenge and make it count!
Are you carrying out work on behalf of charities?
Would you like to do more in this area?
If the answer is yes, tell the industry by entering the new, Charity Challenge today.
Enter now and take the next step in your career
The PharmaTimes Marketer of the Year Awards will return to London in November, alongside Communications Team of the Year and the all-new Sales Awards. Get involved with the 25th anniversary celebrations as this unique competition continues to raise standards, drive innovation and put patient outcomes at the centre of healthcare marketing.
Have you entered the PharmaTimes Sales Awards yet?
If not, you should. Now!
Dr Jim Golby PhD FCIPD, co-chair of the competition’s executive steering group (ESG) says: “I strongly believe that the newly imagined 2018 Pharma Sales Awards will provide a superb methodology for identifying and recognising the very best sales professionals in our Industry today.”
Genmab/Novatis’ Arzerra fails to hit NHL targets
Adding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin’s lymphoma.
US clears first enzyme therapy for PKU
Biomarin’s Palynziq has been approved as the first enzyme therapy to treat the rare brain-threatening genetic disease phenylketonuria (PKU) in adults in the US.
